Topical chemotherapy for burns using cerium salts and silver sulfadiazine.
These experimental data indicate that cerium compounds exert a measurable antimicrobial action in vitro. In vivo the simultaneous use of cerium sulfadiazine and silver sulfadiazine was more effective than silver sulfadiazine alone or the combination of cerous nitrate and silver sulfadiazine. When cerous nitrate was used clically, gram-positive bacteria predominated. In contrast, wounds exposed to silver salts alone harbor a predominately gram-negative flora. The combination of cerous nitrate and silver sulfadiazine appears to provide a broad spectrum inhibitory to both types of organisms. It is apparent that a sampling problem exists in any attempt to monitor wounds that may exceed a square meter in extent. These bacteriologic data pertain only to the surface flora. The need to culture tissue samples of burn wounds has been emphasized. Our experience, however, is that invasion of deep tissue without dense surface colonization, greater than 10(5), is infrequent. Furthermore, fragments of eschar were submitted regularly for culture; those results confirmed the surface culture findins. The characteristic yellow-green color of cerium nitrate treated eschars may results from oxidation of trivalent cerium to yellow ceric ions. Free silver and sulfadiazine ions are available also in small amounts because of limited ionization of the highly insoluble silver sulfadiazine. This might promote the in vivo formation of cerous sulfadiazine and would provide a continuous source of ionic cerium for microbial inhibition. The modification of silver sulfadiazine cream by incorporating cerous nitrate into it strikingly enhances its topical antiseptic effect in burn wounds without increasing toxicity.
D000287:Administration, Topical; D000818:Animals; D001424:Bacterial Infections / Q000517:prevention & control; D002056:Burns / Q000188:drug therapy* / Q000401:mortality; D002563:Cerium / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D051379:Mice; D051381:Rats; D012492:Salts / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012837:Silver Sulfadiazine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D013411:Sulfadiazine / Q000008:administration & dosage*; D014481:United States
D012492:Salts; D013411:Sulfadiazine; D002563:Cerium; D012837:Silver Sulfadiazine